Miles Maxwell

Sustained limitation of myocardial necrosis 24 hours after coronary artery occlusion: Verapamil infusion in dogs with small myocardial infarcts

Derek M. Yellon, David J. Hearse, Miles Maxwell et al. · The American Journal of Cardiology · 1983 · 56 citations

Myocardial Necrosis 24, Cardiovascular Disease, Myocardial Infarction +9

The Time Course of Cardioprotection Induced by GR79236, a Selective Adenosine A1-Receptor Agonist, in Myocardial Ischaemia-Reperfusion Injury in the Pig

James B. Louttit, A. A. E. Hunt, Miles Maxwell et al. · Journal of Cardiovascular Pharmacology · 1999 · 54 citations

Heart Failure, Cardiovascular Pharmacology, Pharmacotherapy +18

Synthesis and Serotonergic Activity of Substituted 2,<i>N</i>-Benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-<i>N</i>,<i>N</i>-dimethyltrypt- amine Derivatives:  Novel Antagonists for the Vascular 5-HT_1B-like Receptor

Gerard P. Moloney, Graeme R. Martin, Neil Mathews et al. · Journal of Medicinal Chemistry · 1999 · 43 citations · Full text

Particle-induced coronary vasoconstriction during cardioplegic infusion

David J. Hearse, Çetin Erol, Lary A. Robinson et al. · Journal of Thoracic and Cardiovascular Surgery · 1985 · 36 citations

Cardiogenic Shock, Cardiovascular Disease, Physiology +4

Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist

Dennis L. Sprecher, Miles Maxwell, Joanne Goodman et al. · European Journal of Pharmacology · 2015 · 25 citations

Molecular Pharmacology, Signal Transduction, Biochemistry +8